4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting, taking place December 6-10, 2024, in Los Angeles. Using analysis from an open-label, long-term treatment study of the RNS® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal electrographic activity) and clinically meaningful reduction ( 50

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is

BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows: The Stifel Healthcare Conference in New York CityMonday, November 18, 2024, at 1:15pm ET The Jefferies London Healthcare ConferenceWednesday, November 20, 2024, at 4:00pm GMT/11am ET Interested parties may access the live and archived webcasts under the "Investors" section of the company's website

BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced presentations at two upcoming medical conferences: the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress (EEC) in Rome, Italy, September 7-11, 2024, and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta, Ga., September 25-26, 2024. At EEC, Rapport will present on the novel design of a Phase 2a proof-of-concept trial for the company's lead product

BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences: The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Thursday, September 5, 2024, at 4:50 pm ET.TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on Thursday, September 26, 2024, at 11:40 am ET. Interested parties may access a live and archived webcast of the Morgan Stanley

- Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl - - Strong cash position of $219 million at the end of Q2 will support multiple clinical readouts - Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "Our tea

Completed initial public offering, raising $174.4 million in gross proceeds, including full exercise of the underwriters' option to purchase additional shares and a concurrent private placement, to fund clinical development of precision neuroscience pipelinePhase 2a trial of RAP-219 in focal epilepsy initiation on track, with topline data expected in mid-2025 On track to begin two additional proof of concept clinical trials of RAP-219 in patients with peripheral neuropathic pain in 2H 2024, and patients with bipolar disorder in 2025Terry-Ann Burrell, who was recently appointed as vice chairman of investment banking at JPMorgan, will transition off the Board of Directors of Rapport following

BOSTON and SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced that the Company will present preclinical data on RTX-1738, an analog to Rapport's lead product candidate RAP-219, across a variety of acute and chronic pain models at the upcoming International Association for the Study of Pain (IASP) 2024 World Congress on Pain taking place August 5-9, 2024, in Amsterdam, Netherlands. RTX-1738 demonstrated analgesic activity across a broad range of preclinical pa

BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Rapport's shares began trading on the Nasdaq Global Market on June 7, 2024, under the ticker symbol "RAPP.

TD Cowen analyst Joseph Thome initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating.

Jefferies analyst Andrew Tsai initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $35.

Stifel analyst Paul Matteis initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $35.

Shares of Contango Ore, Inc. (NYSE:CTGO) fell sharply during Tuesday's session after the company announced pricing of $15 million underwritten public offering. Contango Ore shares dipped 18.4% to $20.34 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Trio Petroleum Corp. (NYSE:TPET) shares jumped 88.2% to $0.4254 after the company completed its first two exploratory wells. Airship AI Holdings, Inc.  (NASDAQ:AISP) shares climbed 32.5% to $4.1599. Airship AI announced a six-figure sole-source contract award within the Department of Justice for Acropolis Enterprise Video and Data Management Platform. Blue World Acquisition Corporation (NASDAQ

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

3 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

3 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

3 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

3 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)